What technology area does this patent fall under?

Primary CPC classification C07K14/5443. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

US11932675B2 · US · B2

Patent metadata
Field	Value
Publication number	US-11932675-B2
Application number	US-202017067508-A
Country	US
Kind code	B2
Filing date	Oct 9, 2020
Priority date	Oct 11, 2019
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising a variant IL-15 protein as compared to SEQ ID NO:2, said variant IL-15 protein comprising an amino acid modification selected from the group consisting of N71Q, N79Q, N112Q, S114del and S114A. 2. A pharmaceutical composition comprising the composition comprising a variant IL-15 protein according to claim 1 and a pharmaceutically acceptable carrier. 3. The composition according to claim 1 , wherein said variant IL-15 protein further comprises an amino acid modification selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D and Q108E. 4. The composition according to claim 1 , wherein said variant IL-15 protein comprises amino acid modifications selected from the group consisting of N71Q/N79Q, N71Q/N79Q/N112Q, N71Q/N79Q/S114del and N71Q/N79Q/S114A. 5. The composition according to claim 1 , wherein said variant IL 15 protein comprises amino acid modifications selected from the group consisting of N1D/N4D/D8N, N1D/N4D/N65D, N1D/D30N, N1D/D61N, N1D/D61N/E64Q/Q108E, N1D/E64Q, N1D/N65D, N1D/Q108E, N4D/D30N, N4D/D61N, N4D/D61N/N65D, N4D/D61N/E64Q/Q108E, N4D/E64Q, N4D/N65D, D8N/D61N, D8N/E64Q, D30N/E64Q, D30N/N65D, D30N/E64Q/N65D, D30N/Q180E, D61N/E64Q/N65D, E64Q/N65D, E64Q/Q108E and N65D/Q108E. 6. The composition according to claim 1 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q. 7. The composition according to claim 1 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/N65D. 8. The composition according to claim 1 , wherein said variant IL-15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/E64Q/N65D. 9. The pharmaceutical composition according to claim 2 , wherein said variant IL-15 protein further comprises an amino acid modification selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D and Q108E. 10. The pharmaceutical composition according to claim 2 , wherein said variant IL-15 protein comprises amino acid modifications selected from the group consisting of N71Q/N79Q, N71Q/N79Q/N112Q, N71Q/N79Q/S114del and N71Q/N79Q/S114A. 11. The pharmaceutical composition according to claim 2 , wherein said variant IL 15 protein comprises amino acid modifications selected from the group consisting of N1D/N4D/D8N, N1D/N4D/N65D, N1D/D30N, N1D/D61N, N1D/D61N/E64Q/Q108E, N1D/E64Q, N1D/N65D, N1D/Q108E, N4D/D30N, N4D/D61N, N4D/D61N/N65D, N4D/D61N/E64Q/Q108E, N4D/E64Q, N4D/N65D, D8N/D61N, D8N/E64Q, D30N/E64Q, D30N/N65D, D30N/E64Q/N65D, D30N/Q180E, D61N/E64Q/N65D, E64Q/N65D, E64Q/Q108E and N65D/Q108E. 12. The pharmaceutical composition according to claim 2 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q. 13. The composition according to claim 2 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/N65D. 14. The composition according to claim 2 , wherein said variant IL-15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/E64Q/N65D. 15. The composition according to claim 14 , wherein said variant IL-15 protein comprises the amino acid sequence of SEQ ID NO: 319.

Assignees

Inventors

Classifications

C07K14/5443Primary
IL-15 · CPC title
A61P35/00
Antineoplastic agents · CPC title
C07K16/2818
against CD28 or CD152 · CPC title
A61K38/00
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
C07K2319/30
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

Patent family

Related publications grouped by family.

View patent family 73498256

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11932675B2 cover?: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and t…
Who is the assignee on this patent?: Genentech Inc, Xencor Inc
What technology area does this patent fall under?: Primary CPC classification C07K14/5443. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).